The United States will restrict routine Covid-19 boosters to people over 65 or those at higher risk of serious illness, while ...

The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine, but with unusual ...

Federal health officials will no longer routinely approve annual COVID-19 shots for younger adults and children who are ...

Top officials in the Trump administration on Tuesday announced they will limit the approval of new COVID-19 vaccines to ...

"The FDA will approve vaccines for high-risk persons and, at the same time, demand robust, gold-standard data on persons at ...

Results showed that replacing a half-hour of sedentary time with a half-hour of moderate-to-vigorous physical activity every ...

Advisers to the U.S. Food and Drug Administration will discuss recommendations for updated COVID-19 vaccines ahead of the ...

The FDA also gave full approval to the Novavax COVID vaccine (Nuvaxovid) using this approach, approving it for those ages 65 ...

The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness from ...

The agency will narrow its approval for updated coronavirus vaccines, marking a significant shift in the agency’s approach to ...

The U.S. Food and Drug Administration plans to require new clinical trials for approval of annual COVID-19 boosters for ...